Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in Cerebrospinal fluid

Clinical Chemistry

Volumn 60, Issue 7, 2014, Pages 987-994

  Leinenbach, Andreas ^a   Pannee, Josef ^b   Dülffer, Thomas ^a   Huber, Andreas ^a   Bittner, Tobias ^a   Andreasson, Ulf ^b   Gobom, Johan ^b   Zetterberg, Henrik ^b,c   Kobold, Uwe ^a   Portelius, Erik ^b   Blennow, Kaj ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CARBON 13; NITROGEN 15; STABLE ISOTOPE;

AMINO ACID ANALYSIS; AQUEOUS SOLUTION; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; ISOTOPE LABELING; LABORATORY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; RADIOISOTOPE DISTRIBUTION; SOLID PHASE EXTRACTION;

AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CALIBRATION; CARBON ISOTOPES; CHROMATOGRAPHY, LIQUID; HUMANS; NITROGEN ISOTOPES; PEPTIDE FRAGMENTS; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 84903703012     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.220392     Document Type: Article

References (25)

1. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-44.
2. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta (40) and Abeta (42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:357-67.
3. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsater H, Anckarsater R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis 2010;2010.
4. Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, et al. Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid beta42. Biomark Med 2012;6:409-17.
5. Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloidbeta1-42 and tau proteins as Alzheimer disease biomarkers. Clin Chem 2013;59:903-16.
6. The Swedish Parliament. Lag (2002:297) om biobanker i hälso-och sjukvården m.m. [Act (2002:297) concerning biobanks in health care, etc.]. http://www.riksdagen. se/sv/Dokument-Lagar/Lagar/Svenskforfattningssamling/Lag- 2002297-ombiobankeri-sfs-2002-297/#K2 (Accessed May 2014; reaccessed June 2014).
7. Jemal M, Schuster A, Whigan DB. Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: method validation, demonstration of use of a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard. Rapid Commun Mass Spectrom 2003;17:1723-34.
8. Li W, Cohen LH. Quantitation of endogenous analytes in biofluid without a true blank matrix. Anal Chem 2003;75:5854-9.
9. Ahmadkhaniha R, Shafiee A, Rastkari N, Kobarfard F. Accurate quantification of endogenous androgenic steroids in cattle's meat by gas chromatography mass spectrometry using a surrogate analyte approach. Anal Chim Acta 2009;631:80-6.
10. Dillen L, Cools W, Vereyken L, Timmerman P. A screening UHPLC-MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species. Bioanalysis 2011;3:45-55.
11. Lame ME, Chambers EE, Blatnik M. Quantitation of amyloid beta peptides Aβ (1-38), Aβ (1-40), and Aβ (1-42) in human cerebrospinal fluid by ultraperformance liquid chromatography-tandem mass spectrometry. Anal Biochem 2011;419:133-9.
12. Peterson AC, Russell JD, Bailey DJ, Westphall MS, Coon JJ. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics 2012;11:1475-88.
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of analytical procedures: text and methodology Q2 (R1). ICH harmonised tripartite guideline. Current Step 4 version. 2005. http://www.ich.org/fileadmin/Public-Web-Site/ICH- Products/Guidelines/Quality/Q2-R1/Step4/Q2-R1-Guideline.pdf (Accessed February 2014).
14. International Organization for Standardization. ISO guide 15193. In vitro diagnostic medical devices: measurement of quantities in samples of biological origin; requirements for content and presentation of reference measurement procedures. Geneva, Switzerland: ISO, 2009.
15. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-4.
16. Bonfiglio R, King RC, Olah TV, Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom 1999;13:1175-85.
17. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019-30.
18. Kushnir MM, Rockwood AL, Nelson GJ, Yue B, Urry FM. Assessing analytical specificity in quantitative analysis using tandem mass spectrometry. Clin Biochem 2005;38:319-27.
19. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkelso C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 2001;47:1776-81.
20. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 2003;352:67-9.
21. International Organization for Standardization. ISO guide 98-3. Uncertainty of measurement-part 3: guide to the expression of uncertainty in measurement. Geneva, Switzerland: ISO, 2008.
22. Campbell J, Rezai T, Prakash A, Krastins B, Dayon L, Ward M, et al. Evaluation of absolute peptide quantitation strategies using selected reaction monitoring. Proteomics 2011;11:1148-52.
23. Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, et al. A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ38, Aβ40, and Aβ42 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. J Alzheimers Dis 2013;33:1021-32.
24. Thienpont LM, Stepman HC, Vesper HW. Standardization of measurements of 25-hydroxyvitamin D3 and D2. Scand J Clin Lab Invest Suppl 2012;243:41-9.
25. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013;9:251-61.